Status:
COMPLETED
A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes
Lead Sponsor:
Chiesi UK
Collaborating Sponsors:
Gesellschaft für Therapieforschung mbH
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (bec...
Detailed Description
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (bec...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age,
- Patients with confirmed leading diagnosis of asthma with or without concomitant COPD,
- Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS,
- Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.
Exclusion
- 1\) Participation in an interventional clinical trial within 30 days prior to enrolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.
Key Trial Info
Start Date :
June 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 14 2024
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT04902573
Start Date
June 17 2021
End Date
June 14 2024
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Haven Surgery, The Haven, Burnhope,
Durham, County Durham, United Kingdom, DH7 0BD